In combination with Pfizer’s CDK4/6 inhibitor Ibrance (palbociclib) and anti-oestrogen drug Faslodex (fulvestrant), Itovebi ...

The CBD-based cream reduced UVA damage, preventing nuclear and mitochondrial DNA mutations associated with skin ageing and ...

ANI Pharmaceuticals has commenced a Phase IV trial to compare two dosage levels of Purified Cortrophin Gel for acute gout ...

At CTO West Coast, an expert discussed the implications of the FDA’s expedited approval programmes with a spotlight on ...

Tango Therapeutics has announced the first subject dosing in the open-label, multi-centre TNG456 Phase I/II trial.

Merck KGaA said that cohort A met the primary endpoint in the Phase II lupus trial but cohort B failed to meet its primary ...

Satellos said that following the Phase I data, it will be advancing its DMD small molecule to a Phase II trial.

AnnJi Pharmaceutical has reported encouraging outcomes from its randomised, placebo-controlled Phase I/IIa trial of AJ201.

Olezarsen is a promising treatment for severe hypertriglyceridemia, familial chylomicronemia syndrome and other dyslipidemia.

Sarepta Therapeutics has announced new outcomes from its Phase Ib Study 9001-103, named Endeavour, of Elevidys for DMD.

Rejuvenate Biomed has dosed the first subject in the randomised Phase II trial to assess its lead compound, RJx-01.